MIV Therapeutics Claims of Total Biocompatibility of Hydroxyapatite Confirmed by Independent Scientific Studies.

VANCOUVER, British Columbia -- Japanese Studies Report Blood Compatibility, Protein Adsorption and Thrombus-Free Performance of Hydroxyapatite 

MIV Therapeutics, Inc. (OTCBB: MIVT) a developer of next-generation biocompatible stent coatings and drug delivery technologies, has summarized the results of two independent Japanese studies that found strong blood compatibility, adsorption of proteins, and overall biological safety of hydroxyapatite in blood. The two studies add important independent substantiation to MIVT's own reports of exceptional biocompatibility and safety of the Company's proprietary hydroxyapatite-based coating technology for cardiovascular stents and medical devices.

MIVT has developed proprietary technology that use hydroxyapatite (HAp) to create advanced biocompatible and drug-eluting coatings for cardiovascular stents and other implantable medical devices.

Two independent Japanese studies found that HAp demonstrated exceptional performance and safety across several tested parameters in tests involving human blood samples, significantly bolstering and validating MIVT's proprietary technology and product development initiatives in multi-billion-dollar markets for coronary stents, and other medical devices, such as implantable drug-delivery systems. The studies provide additional validation of MIVT's claims of exceptional biocompatibility and safety of the Company's proprietary HAp-based coating technology, recently reinforced by positive outcomes of comprehensive animal studies. MIVT's HAp technology is entering the final stages of evaluation in preparation for commercial introduction for use as an advanced coating for cardiovascular stents and other medical devices.

"Both studies confirmed MIVT's long-standing expectations and findings regarding the exceptional biocompatibility and safety of hydroxyapatite," said Mr. Lindsay. "Observations by the Japanese scientists are totally in line with the outcomes of our own comprehensive biocompatibility studies performed on stents with MIVT's proprietary HAp coating by the independent testing authority, Toxicon Corporation. Preliminary conclusions from our comprehensive animal studies on hydroxyapatite-coated stents, which we are currently conducting, also confirm the total absence of undesirable side effects when hydroxyapatite is in contact with blood in cardiovascular applications. We expect to publish more detailed information on the progress of our advance studies in the near future."

In one of the Japanese studies, scientists from the Biomaterials Laboratory, Faculty of Engineering at Okayama University in Japan examined the blood compatibility and protein adsorption of hydroxyapatite and hydroxyl-carbonate apatites. Blood compatibility and clotting properties were evaluated with three key parameters which are known to have a detrimental effect on potential blood clotting: active partial thromboplastin time (PTT), prothrombin time (PT), and the amount of fibrinogen (Fib).During the study titled "Selective protein Adsorption and Blood Compatibility of Hydroxy-carbonate Apatites", samples of hydroxyapatite were exposed to fresh plasma extracted from human blood. Protein adsorption was also evaluated in solutions of bovine serum albumin (BSA) to simulate a healthy person, and in solutions to test the effects in a person suffering from amloidosis, a condition in which insoluble protein fibers tend to deposit in organs, preventing their proper function. This condition is considered one of the key factors that promote chronic infection or chronic inflammatory disease frequently encountered during cardiovascular interventions involving stent implantation or other procedures. The study confirmed total biocompatibility and safety of hydroxyapatite when exposed to direct contact with blood.

The scientists at Okayama University concluded: "The clotting properties (partial thromboplastin time, prothrombin time and the amount of fibrinogen) for plasma in contact with samples of hydroxyapatite and plasma which did not have any contact with hydroxyapatite were the same."

An earlier study performed by another group of scientists at the Bioceram Division of Kyocera Corporation in Gamo, Japan, evaluated deposition of fibrins and adhesion of platelets to the hydroxyapatite-coated titanium when exposed to anticoagulated blood, and to washed platelet suspension (WPS). Uncoated, commercial grade titanium plate was used as an experimental control element.

The study concluded: "No thrombus was observed on hydroxyapatite-coated samples, possibly because of the high adsorption of heparin." Heparin, a medication that inhibits reactions that leads to the clotting of blood and the formation of fibrin clots, was applied during this study at a level typically used during medical procedures. In this context, protein adsorption refers to the important bonding phenomenon that occurs between proteins or protein-based drugs and hydroxyapatite, enabling improved drug-eluting characteristics. A thrombus is a blood clot that forms within a blood vessel, and remains attached to its place of origin; such blood clots are a significant source of vascular complications.

About MIV Therapeutics

MIV Therapeutics is developing a next generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and other implantable medical devices. MIVT's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction of metal stents. MIVT's ultra-thin coating has been derived from a unique biocompatible material called hydroxyapatite (HAp) that demonstrated during in-vivo animal trials excellent safety and superior healing properties pursued by the medical science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and received a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development program.

For more information, please visit http://www.mivtherapeutics.com. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe", "will", "breakthrough", "significant", "indicated", "feel", "revolutionary", "should", "ideal", "extremely" and "excited". These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Copyright (C) 2005 MIV Therapeutics Inc. All rights reserved.